GLP-1 agonists aid in weight loss by reducing food cravings and hunger and increasing satiety.4 Certain GLP-1 agonists and GLP-1/GIP agonists are approved by the FDA for type 2 diabetes as well as weight management.4,5 The GLP-1 agonists approved for weight loss are liraglutide (Saxenda; Novo Nordisk) and semaglutide (Wegovy; Novo Nordisk). Summary of EvidenceSeveral studies have shown that chronic management of obesity is recommended even after weight loss to maintain body weight long term. At month 3 after the discontinuation of semaglutide, 29% either lost additional weight or doubled their initial weight loss, 39% maintained their initial weight loss, and 32% had some weight regain or complete weight regain.10 At month 12 after stopping semaglutide, 36% of patients either lost additional weight or doubled their initial weight loss, 20% maintained their initial weight loss, and 44% had some weight regain or complete weight regain.10Researchers also analyzed 17,733 patients over 1 year who completed liraglutide and lost at least 5 pounds. At month 3 after stopping liraglutide, 28% either lost additional weight or doubled their initial weight loss, 33% maintained their initial weight loss, and 32% had some weight regain or complete weight regain.10 At month 12, 35% of patients either lost additional weight or doubled their initial weight loss, 21% maintained their initial weight loss, and 45% had some weight regain or complete weight regain.10These studies demonstrate that both weight loss and weight regain are seen with GLP-1 agonists; however, participants who received placebo also had some weight loss and weight regain, although to a lesser extent. Clinical ImplicationsThese findings suggest that obesity should be treated as a chronic condition, even after weight loss goals have been achieved.